Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Etan Orgel, MD

    TitleAssistant Professor of Clinical Pediatrics
    SchoolKeck School of Medicine of USC
    AddressCHL 4650 W Sunset Blvd,
    Off Campus
    Los Angeles California 90027
    Phone+1 323 361 2121
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Orgel is currently an attending physician on the Medical Supportive Care/Survivorship and Supportive Care Program and the Leukemia and Lymphoma Team within the Division of pediatric Hematology, Oncology, and Blood & Marrow Transplantation at the Children's Hospital Los Angeles (Los Angeles, CA). Dr. Orgel's clinical specialty focuses on higher risk and rare malignant hematology, and specifically, the rare phenomenon of Mixed-Phenotype Acute Leukemia (MPAL). He possesses an academic appointment as an Assistant Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) following strong training in general pediatrics from Children's National Medical Center (Washington, DC) and a pediatric hematology/oncology fellowship at CHLA. This was complemented with didactic clinical trial training via completing a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.

      Dr. Orgel's primary research interest lies in the field of medical supportive care or "cancer control" (reducing acute and late treatment-related toxicities). His specific focus utilizes a translational research approach to target specific toxic effects to widen therapeutic windows for common chemotherapies and/or improve the quality of life of children with cancer. Currently, Dr. Orgel's active research encompasses studying new agents and novel strategies to reduce hearing loss from chemotherapy (cisplatin), to target obesity in pediatric ALL to improve survival, quality of life, and bone health, and to evaluate resistance to asparaginase (a highly-effective chemotherapy agent) in children with relapsed ALL.

      Collapse ORNG Applications 
      Collapse Featured Publications
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2017 Dec 08. PMID: 29218844.
        View in: PubMed
      2. Sheng X, Parmentier JH, Tucci J, Pei H, Cortez-Toledo O, Dieli-Conwright CM, Oberley MJ, Neely M, Orgel E, Louie SG, Mittelman SD. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. Mol Cancer Res. 2017 Nov 08. PMID: 29117945.
        View in: PubMed
      3. Moke DJ, Oberley MJ, Bhojwani D, Parekh C, Orgel E. Association of clinical trial enrollment and survival using contemporary therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Sep 06. PMID: 28876513.
        View in: PubMed
      4. Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A, O'Gorman MRG. Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia. Am J Clin Pathol. 2017 04 01; 147(4):374-381. PMID: 28340210.
        View in: PubMed
      5. Orgel E, Mueske NM, Sposto R, Gilsanz V, Wren TAL, Freyer DR, Butturini AM, Mittelman SD. A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Oct; 58(10):2370-2378. PMID: 28278717.
        View in: PubMed
      6. Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Tolbert VP, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 Nov; 63(11):1943-8. PMID: 27437864.
        View in: PubMed
      7. Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016 Mar; 103(3):808-17. PMID: 26864366.
        View in: PubMed
      8. Orgel E, Mueske NM, Wren TA, Gilsanz V, Butturini AM, Freyer DR, Mittelman SD. Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016 Apr; 85:131-7. PMID: 26851412; PMCID: PMC4795805 [Available on 04/01/17].
      9. Orgel E, Mueske NM, Sposto R, Gilsanz V, Freyer DR, Mittelman SD. Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. Leuk Lymphoma. 2018 Jan; 59(1):138-145. PMID: 26818609.
        View in: PubMed
      10. Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, Counts PA, Murphy D, Dhall G, Freyer DR. Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. Pediatr Blood Cancer. 2016 Mar; 63(3):527-34. PMID: 26529035; PMCID: PMC4724248 [Available on 03/01/17].
      11. Felsenstein S, Orgel E, Rushing T, Fu C, Hoffman JA. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J. 2015 Apr; 34(4):e78-84. PMID: 25764103.
        View in: PubMed
      12. Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H, Mittelman SD. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014 Dec 18; 124(26):3932-8. PMID: 25349177.
        View in: PubMed
      13. Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, Freyer DR. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol. 2014 May 01; 32(13):1331-7. PMID: 24687836; PMCID: PMC3992723.
      14. Orgel E, Rushing T. Efficacy and tolerability of intravenous pentamidine isethionate for Pneumocystis jiroveci prophylaxis in a pediatric oncology population. Pediatr Infect Dis J. 2014 Mar; 33(3):319-21. PMID: 24030353.
        View in: PubMed
      15. Orgel E, Ji L, Pastor W, Schore RJ. Infectious morbidity by catheter type in neutropenic children with cancer. Pediatr Infect Dis J. 2014 Mar; 33(3):263-6. PMID: 24263218.
        View in: PubMed
      16. Murphy D, Orgel E, Termuhlen A, Shannon S, Warren K, Quinn GP. Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late! Front Oncol. 2013 Oct 07; 3:248. PMID: 24109589; PMCID: PMC3791875.
      17. Orgel E, Mittelman SD. The links between insulin resistance, diabetes, and cancer. Curr Diab Rep. 2013 Apr; 13(2):213-22. PMID: 23271574; PMCID: PMC3595327.
      18. Orgel E, Zung L, Ji L, Finklestein J, Feusner J, Freyer DR. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer. 2013 Sep; 60(9):1528-33. PMID: 23441080.
        View in: PubMed
      19. Orgel E, Jain S, Ji L, Pollick L, Si S, Finlay J, Freyer DR. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer. 2012 Jun; 58(6):953-8. PMID: 21796767.
        View in: PubMed
      20. Orgel E, McCarter R, Jacobs S. A failing medical educational model: a self-assessment by physicians at all levels of training of ability and comfort to deliver bad news. J Palliat Med. 2010 Jun; 13(6):677-83. PMID: 20597701.
        View in: PubMed